Biological Storage Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Biological Storage Facility


Vindon’s UK storage suite based in Rochdale offers 2000 cubic meters of controlled environment storage space, providing pharmaceutical stability storage at all World Climatic ICH conditions as well as bespoke conditions.

Biological storage at low and ultra-low temperatures is available at temperatures from -20ºC to -80ºC. Vindon’s Ultra-low temperature facility can store millions of samples, vials or tube racks and annual validation and servicing by our in-house engineers ensures the most reliable storage solution.

Vindon’s HTA licensed Cryobank uses DryStore freezers for cryogenic storage at minus 190ºC, vapour phase storage systems designed to ensure against sample contamination. Our state of the art biorepository provides secure storage for stem cells, cord stem cells, biological samples, DNA and Bone Marrow.

Vindon Scientific also has IMB-certified storage facilities in Tramore, Ireland and storage suites in Kennesaw, near Atlanta, Georgia in the USA and from mid 2013 in Orange County, California, USA.

On-site engineers monitor equipment and undertake preventive maintenance with back-up generators providing additional security in the event of power failure.

Vindon engineers offer a full Validation and Calibration service using a combination of UKAS (United Kingdom Accreditation Service) calibrated equipment and state-of-the-art data acquisition systems, Vindon’s qualified and experienced engineers are extensively trained in the validation and calibration of any make/model of environmental chamber as well as our own Vindon manufactured product.

Vindon UK

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here